Atossa Genetics announced it has signed an agreement with Fisher HealthCare, Inc. (part of Thermo Fisher Scientific) to distribute ForeCYTE Breast Health devices.
Atossa’s ForeCYTE Breast Health device consists of the patented MASCT pump and ForeCYTE patient collection kits. Physicians and nurses utilize the MASCT system to collect small amounts of nipple aspirate fluid for cytological and genomic analysis, which is conducted at Atossa’s wholly owned National Reference Laboratory for Breast Health.
The ForeCYTE test, touted as “the Pap smear for breast cancer,” is a noninvasive procedure that is both painless and fast. Performed in a physician’s office, the test provides crucial early detection of precancerous conditions, which can progress to cancer over a period of approximately eight years before mammography or other means can detect it. The test is intended for the around 110 million women in the United States who are between the ages 18-73, including younger women and women with dense breasts, breast implants, or BRCA gene mutations.
It is Atossa Genetics’ goal, through the ForeCYTE test, to reduce the unyieldingly high rates of breast cancer through early detection and treatment of precursor changes leading to the disease, just as the Pap smear has led to a more than 70 percent reduction in cervical cancer rates. Through the company’s partnership with Fisher HealthCare, the test will be made available to women throughout the U.S.
“Fisher HealthCare is a recognized leader in providing diagnostic solutions to customers in the acute care, physician office and reference lab markets, and we are excited to have entered into this distribution agreement,” said Atossa Genetics Chairman, CEO and President Dr. Steven Quay. “We believe our ForeCYTE test represents a significant breakthrough in breast cancer risk assessment, and we look forward to working with our partners to make the ForeCYTE test a standard of care.”
For more information about the ForeCYTE Breast Health Risk Assessment Test, visit www.atossagenetics.com
Let us hear your thoughts below:
